ArticleAmerican journal of cancer research2018

Patients with RAS wild-type right-sided unresectable liver-confined mCRC also benefit from cetuximab plus chemotherapy in first-line treatment.

Peng Zheng et al.PubMed ↗Full text ↗

No numbers read from the abstract.